Peptide education
TB-500
Ac-LKKTETQ · Thymosin beta-4 17-23 fragment · Thymosin beta-4 fragment · Tbeta4 fragment
TB-500 is the name on a thousand recovery vials, and the first thing to know is that it is not really a drug name at all. In the clearest analytical literature it refers to Ac-LKKTETQ, a seven-amino-acid acetylated fragment cut from thymosin beta-4. Sellers use the name loosely for anything thymosin-related, which is why half the confusion here is about identity rather than effect. The TB-500-specific evidence is two papers deep: one that pinned down what the molecule is, and one that watched it work in cell cultures and rats. Direct human efficacy data for the fragment does not exist in these sources.
Everything solid about TB-500 says what the fragment is and what it does in rats and cell cultures. Every human outcome people cite for it belongs to full-length thymosin beta-4, a different molecule.
Overview
Quick answer
TB-500, full-length thymosin beta-4, and Wolverine Blend are separate topics. Full-length thymosin beta-4 is a 43-amino-acid peptide with its own human development records. Wolverine Blend is a BPC-157 plus TB-500 market product. Standalone TB-500 starts with a different problem: fragment identity and gray-market product claims drive much of the discussion before any benefit claim can be judged.
What is TB-500?
In the one solid analytical paper on it, TB-500 is Ac-LKKTETQ: an N-terminally acetylated fragment covering the 17-23 region of thymosin beta-4. On a vendor label it can mean that fragment, the full-length protein, or material that was never characterized, which is why identity comes before every other question here.
What do people use or discuss it for?
Injury recovery, almost entirely: tendons, ligaments, muscle strains, joint problems, wound healing, flexibility, and comeback stories after training layoffs. It is also half of the BPC-157 stacks sold as Wolverine Blend. Those are market themes; none of them is a measured human outcome for the fragment.
What route, amount, and schedule details are documented?
None from human studies, because there are no human studies of the fragment in this source set. Community protocols describe a loading phase of 2 to 2.5 mg twice weekly for 4 to 6 weeks, then maintenance every week or two, all subcutaneous. That schedule circulates because people copy it, not because anyone tested it.
What source details matter?
Whether the source is about the fragment or the full-length protein. Human thymosin beta-4 trials, eye-drop products, and blend reports all get cited as TB-500 evidence, and none of them are. The TB-500-specific file is a 2012 identification paper and a 2024 study that quantified the fragment and screened wound activity in vitro and in rats. That is the whole file.
Reported practice
Commonly reported protocol
Community loading-and-maintenance protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
A PubMed-indexed analytical paper identifies TB-500 around the N-terminal acetylated 17-23 fragment of thymosin beta-4, Ac-LKKTETQ. That is identity evidence, not human repair efficacy.
A 2024 PubMed source quantified TB-500 and metabolites in in-vitro experiments and rats and screened wound-healing activity. That supports preclinical discussion, not a human recovery claim.
No direct human exposure, safety, or efficacy data for the TB-500 fragment were found. Adjacent full-length thymosin beta-4 records remain comparison material.
FDA compounding materials discuss peptide bulk substances that may present significant safety risks, and TB-500 appears in PCAC-related review context. Those sources raise quality concerns rather than clearing gray-market products for use.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| TB-500 repairs tendons, ligaments, or muscle. | No direct human TB-500 fragment efficacy evidence supports this claim. The nearest human material is for full-length thymosin beta-4, not standalone TB-500 recovery outcomes. | The 2024 PubMed paper supports in-vitro and rat wound-activity discussion. That explains the repair rationale, but human tendon, ligament, or muscle outcomes are not in that paper. | Clinics, vendors, online regimen pages, and forums commonly use TB-500 in repair and recovery language. Many clinic and vendor pages use TB-500 and thymosin beta-4 interchangeably, even though the fragment and full-length peptide are different materials. | TB-500 is widely marketed and discussed for recovery, but TB-500-specific support is still mostly identity work and preclinical biology. |
| TB-500 has the same evidence as full-length thymosin beta-4. | The full-length thymosin beta-4 ClinicalTrials source is useful comparison material. It helps prevent name confusion; it does not upgrade the TB-500 fragment. | A fragment can share part of a parent peptide's biological rationale, but fragment length, acetylation, metabolism, route, exposure, and product identity can change interpretation. | Gray-market and blend discussions often use TB-500, TB4, and thymosin beta-4 language loosely. That loose naming is a reason to separate the products, not to merge the evidence. | Keep TB-500 fragment, full-length thymosin beta-4, and blend products separate because each can involve a different molecule, route, exposure, and product-quality question. |
| A TB-500 vial has a known human dose or cycle. | The available TB-500 material does not provide a human amount, use frequency, or cycle length. Full-length thymosin beta-4 studies and blend-adjacent reports do not create a standalone TB-500 regimen. | Wound-activity biology does not determine a safe or effective human amount. Dose translation from rats, cell systems, parent peptides, or vendor vial sizes is not clinical dosing evidence. | Online schedules are usually injection-centered and often copied through peptide communities, but they are inconsistent and frequently detached from a verified product identity. | The cited material does not give a controlled standalone human TB-500 regimen. |
| TB-500 has a human wound-healing mechanism. | No human wound-healing outcome study was found for the TB-500 fragment. | The in-vitro and rat study supports wound-activity screening and metabolite quantification. That is useful preclinical evidence, but it remains below human efficacy. | Wound-healing and soft-tissue claims are common in peptide marketing and personal-use reports. Those reports can show why the topic is discussed, but they cannot separate the fragment from product identity, co-use, rehab, time, or placebo effects. | Say "preclinical wound-activity evidence," not human wound-healing evidence. |
| Product testing or a COA makes TB-500 safe to inject. | A product test is not a human safety study. FDA compounding materials flag peptide-related safety and quality questions that go beyond the name on a vial. | The quality questions are identity, sterility, endotoxin, impurities, degradation, concentration, storage, and whether the material is the intended fragment rather than full-length thymosin beta-4 or something else. | Gray-market pages may combine research-use disclaimers, repair claims, purity percentages, and vial-size language. That mix is a product-risk warning, not clinical validation. | Not enough. A COA can be one document to inspect, but it is not finished injectable safety or human-benefit evidence. |
Bottom line
Main takeaway
TB-500 is a fragment of the repair protein thymosin beta-4, sold for recovery on the strength of the parent protein's reputation. No human study of the fragment itself exists in these sources.
Before comparing claims, ask which molecule the source actually studied: Ac-LKKTETQ, full-length thymosin beta-4, or a vial that just says TB-500. Most confident claims collapse the three into one.
The TB-500-specific record is the 2012 identification paper, the 2024 in-vitro and rat wound-activity paper, and FDA compounding material. Everything human belongs to full-length thymosin beta-4 and stays on that page.
Identity
What it is
TB-500, in the literature that actually names it, is Ac-LKKTETQ: a seven-amino-acid acetylated fragment of thymosin beta-4, mapped to the 17-23 region of the parent protein. A 2012 doping-analysis paper established that identity because the fragment was turning up in underground products.
The appeal is inherited. Thymosin beta-4 sequesters actin, drives cell migration and wound-edge behavior, and carries a real research history in wound, cardiac, and dermal models. A fragment that captures part of that biology is an obvious thing to try. A 2024 study quantified TB-500 and its metabolites and screened wound-healing activity in vitro and in rats: genuine preclinical support, and also the ceiling of the direct evidence.
What the market sells under the name is less tidy. TB-500 can mean the fragment, a loose shorthand for full-length thymosin beta-4, an uncharacterized vial, or one half of a Wolverine Blend. FDA compounding material flags the fragment for missing human exposure data, so the label alone settles nothing.
How people talk about it online
Online, TB-500 is recovery talk: tendons, ligaments, joints, strains, wound healing, mobility, getting back to training. The standard protocol circulating is a loading phase of 2 to 2.5 mg twice weekly for 4 to 6 weeks, then maintenance of the same dose every week or two, injected subcutaneously.
That schedule is one of the strongest community conventions on this site, and it has no trial behind it. It propagated through forums and protocol blogs, detached from any verified product identity, and the vials it assumes are fragments rather than the studied full-length protein.
Much of the discussion is really blend discussion: TB-500 plus BPC-157, sold as Wolverine Blend. Blend packaging tells you how the market positions the fragment; it adds no standalone evidence.
Use context
Routes, doses, and cycle patterns
The standalone TB-500 material does not identify a controlled human route, amount, frequency, or cycle. It supports a narrower conclusion: fragment identity is documented, wound activity is preclinical, full-length thymosin beta-4 human studies are adjacent, and gray-market injection patterns remain uncontrolled.
Human studies and product labels
TB-500 / Ac-LKKTETQ identification
- Purpose
- Molecule identity and name separation
- Context
- PubMed analytical characterization paper
- Route
- Analytical identity source, not a route study
- Amount
- No standalone human amount in this source
- Frequency
- No standalone human frequency in this source
- Duration
- No standalone human duration in this source
Use this to identify TB-500 as an acetylated thymosin beta-4 fragment. It is not recovery efficacy evidence.
TB-500 in-vitro and rat wound-activity work
- Purpose
- Preclinical wound-activity and metabolite screening
- Context
- PubMed in-vitro and rat study
- Route
- In-vitro experiments and rat exposure
- Amount
- Preclinical exposure only; no standalone human amount
- Frequency
- Preclinical exposure only; no standalone human frequency
- Duration
- Preclinical exposure only; no standalone human duration
This is the best TB-500-specific repair-biology source. It supports preclinical interpretation rather than a human recovery protocol.
Full-length thymosin beta-4 adjacent trial
- Purpose
- Preventing TB-500 and TB-4 claim mixing
- Context
- ClinicalTrials.gov record for full-length thymosin beta-4
- Regimen
- No single reliable dose, schedule, or cycle showed up in the materials reviewed.
- Frequency
- Not a TB-500 fragment schedule
- Duration
- Not a TB-500 fragment cycle
That source is for full-length thymosin beta-4. It is helpful for comparison and naming clarity, but it is not standalone TB-500 fragment recovery evidence.
FDA peptide compounding-risk context
- Purpose
- Safety and product-quality caution
- Context
- FDA compounding safety-risk and PCAC materials
- Route
- Not route guidance
- Amount
- Not dosing guidance
- Frequency
- Not schedule guidance
- Duration
- Not cycle guidance
FDA materials support caution around peptide bulk substances, missing safety information, and product quality. They do not approve TB-500 or validate market vials.
Real-world discussion
Community loading-and-maintenance protocols
- Purpose
- Injury recovery and flexibility discussion
- Context
- Forums, clinics, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Community protocols usually describe a loading phase of 2 to 2.5 mg twice weekly, followed by a maintenance phase of 2 to 2.5 mg every one to two weeks.
- Frequency
- Twice weekly while loading, then weekly or every other week in most descriptions
- Duration
- Loading commonly described as 4 to 6 weeks, with maintenance sometimes open-ended
The loading-then-maintenance pattern is the strongest community convention for TB-500, but it has no controlled human trial behind it, and TB-500 fragment products are not the same as full-length thymosin beta-4. Reported as context, not a recommendation.
What varies
- Molecule: identify whether the source means Ac-LKKTETQ/TB-500 fragment, full-length thymosin beta-4, or a blend product.
- Route: injection-centered online use is separate from full-length thymosin beta-4 clinical routes and animal or in-vitro work.
- Amount: no studied human TB-500 amount is available for standalone use.
- Frequency: repeated online use is discussed, but the fragment evidence does not report a dependable human frequency.
- Duration: cycle claims remain market claims unless a study reports a human duration.
- Quality: identity, sterility, endotoxin, impurity profile, concentration, degradation, storage, reconstitution, and lot documentation matter before any vial claim can be interpreted.
Human data
Human evidence
There is no direct human evidence for the TB-500 fragment in this source set: no exposure study, no dose-finding, no efficacy trial, not even a case series. What exists is a 2012 analytical paper establishing the fragment's identity and a 2024 paper with in-vitro and rat wound-activity data. FDA materials note the missing human exposure data and flag immunogenicity and impurity concerns. The full-length thymosin beta-4 registry entries people cite as support involve a different molecule and are comparison material only. Human recovery claims for TB-500 rest entirely on borrowed evidence and community reports.
Evidence maturity
TB-500's story is identity drift: a real research protein behind it, fragment products in front of it, and doping prohibition around both.
Thymosin beta-4 literature across wound, cardiac, and dermal models.
TB-500 products are usually fragments, not the studied full-length protein.
No controlled human outcome data for marketed recovery claims.
Prohibited in sport with LC-MS detection; PCAC voted July 23, 2026 to recommend TB-500 bulk substances for the 503A Bulks List (8-6, one abstention). The recommendation is non-binding; FDA rulemaking follows, so compounding status is unchanged today.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Standalone TB-500 fragment human efficacy | No direct human TB-500 fragment efficacy population found | Evidence gap in the available TB-500 material | Standalone TB-500 / Ac-LKKTETQ | No controlled human recovery, tendon, ligament, muscle, wound, or safety outcome source is available for standalone TB-500. | The evidence supports a narrower conclusion: standalone TB-500 fragment has identity and preclinical wound-activity material, while human recovery claims still rely on adjacent thymosin beta-4 material and market discussion. | Weak |
| TB-500 / Ac-LKKTETQ identification paper | Analytical identity and characterization context | Synthesis and characterization paper | TB-500 fragment identity | Supports the identity of TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4. | Identity evidence is not human exposure, efficacy, safety, or dosing evidence. | Moderate for identity; no human efficacy data |
| In-vitro and rat wound-activity study | In-vitro systems and rats | Quantification, metabolite screening, and wound-activity assessment | TB-500 preclinical activity | Supports preclinical wound-activity discussion for TB-500 and related metabolites. | It does not report a human route, amount, frequency, cycle, clinical outcome, or injectable product-safety record. | Preclinical |
| Full-length thymosin beta-4 adjacent registry | Full-length thymosin beta-4 study population | ClinicalTrials.gov registry context | Adjacent full-length thymosin beta-4 | Shows that related full-length thymosin beta-4 has its own human development context. | Full-length thymosin beta-4 evidence is not standalone TB-500 fragment evidence. | Adjacent human comparison, not TB-500 fragment evidence |
Cautions
Safety and unknowns
- Human safety for standalone TB-500 fragment use is not characterized here.
- Route matters. In-vitro and rat work, adjacent full-length thymosin beta-4 records, and injection-centered gray-market discussion are different exposure situations.
- Repeated cycles, long-term use, stacking with BPC-157 or other recovery peptides, and use after injury or procedures need more than the available TB-500 sources.
- Product identity is a safety issue. A vial labeled TB-500 can differ from the fragment identity, concentration, impurity profile, sterility, endotoxin, degradation, and storage conditions described in research or product paperwork.
- FDA compounding-risk materials support caution around peptide bulk substances with limited safety information and peptide-related quality concerns.
Product quality
A vial label is only a starting point
Dose comparisons are only meaningful when the source identifies Ac-LKKTETQ, full-length thymosin beta-4, a metabolite, or only a product sold as TB-500.
Gray-market vial claims can include purity percentages, third-party test language, research-use disclaimers, and repair claims without documenting sterile injectable quality.
Blend products add another layer because BPC-157 plus TB-500 claims can make standalone TB-500 evidence look more complete than it is.
Fragment identity
The product has to match the intended Ac-LKKTETQ/TB-500 fragment, not a loose thymosin beta-4 label.
Sterility and endotoxin
Injection-centered market use raises contamination questions that a purity percentage leaves open.
Concentration and vial math
A labeled vial amount is not the measured peptide content or a clinically studied human amount.
Impurities and degradation
Synthetic peptides can include related impurities or degradation products that change safety interpretation.
COA chain of custody
A posted test is only useful if it can be tied to the actual lot, method, date, sample handling, and complete assay results.
Mechanism
How it is proposed to work
TB-500 is discussed as a repair peptide because it is related to thymosin beta-4 biology, which is tied to cell movement, actin handling, angiogenesis, and wound-response pathways. For standalone TB-500, the direct evidence is narrower: identity work plus in-vitro and rat wound-activity screening.
The 2012 analytical paper is most helpful for naming and fragment identity. It helps keep Ac-LKKTETQ/TB-500 separate from full-length thymosin beta-4.
The 2024 in-vitro and rat study is most helpful for repair-biology plausibility. It is preclinical evidence, not a study of human outcomes.
Mechanism is useful only when product identity and quality are clear. If the market product is not the intended fragment, is impure, is nonsterile, or uses an unstable formulation, the biological rationale becomes less useful.
Thymosin beta-4's best-characterized molecular role is sequestering monomeric actin, which regulates cytoskeletal dynamics, cell migration, and wound-edge behavior. The Ac-LKKTETQ fragment sold as TB-500 captures only part of that biology.
In cardiac and dermal models the full-length protein also shows pro-angiogenic and anti-fibrotic activity, which is why it drew interest for cardiac repair before any human validation existed.
FAQ
Common questions
Is TB-500 the same as thymosin beta-4?
Not exactly. Products sold as TB-500 are usually fragment-based, while thymosin beta-4 is the full-length 43-amino-acid protein with its own research literature. Claims borrowed from one do not automatically transfer to the other, which makes product identity the first question.
What do people report using for recovery?
Community protocols commonly describe a loading phase of 2 to 2.5 mg twice weekly for 4 to 6 weeks, then maintenance of 2 to 2.5 mg every one to two weeks. This pattern has no controlled human trial behind it.
Does TB-500 have human evidence for injury recovery?
No dependable human evidence. The repair literature is animal and cell work, and the full-length protein's data does not validate fragment products sold under the TB-500 name.
Details
Technical details
Sources
References
- 1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 3.
PMID:38382158 Accessed 2026-06-08.
In vitro and rat source; supports identity/activity mapping, not direct human exposure or efficacy.
- 4.
ClinicalTrials.gov. ClinicalTrials.gov record NCT00382174 2006.
NCT00382174 Accessed 2026-06-08.
Full-length thymosin beta-4 trial record; adjacent to TB-500 fragment discussion, not interchangeable evidence.